Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Teriflunomide HMR1726 · 3 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| teriflunomide (HMR1726) | EXPERIMENTAL | Participants administered 14mg Teriflunomide once daily, oral. For participants who permanently discontinue Teriflunomide, an accelerated elimination procedure with either cholestyramine or charcoal will be administered. |
| Reference population | NO_INTERVENTION | Untreated healthy subjects |
| teriflunomide dose 1 | EXPERIMENTAL | Teriflunomide 14mg tablet, oral single dose, fast condition Cholestyramine power, 8 gram,oral three times a day for 4 days, fed condition |
| Severe impaired renal function | EXPERIMENTAL | Subjects with severe renal impairment as defined by Cockroft-Gault formula |
| Normal renal function | EXPERIMENTAL | Subjects with normal renal function as defined by Cockroft-Gault formula |
| Name | Type | Description |
|---|---|---|
| teriflunomide HMR1726 | DRUG | Pharmaceutical form:tablet Route of administration: oral |
| cholestyramine | DRUG | Pharmaceutical form:powder Route of administration: oral |
| charcoal | DRUG | Pharmaceutical form:granule Route of administration: oral |
Inclusion criteria: Patients (male and female) with relapsing forms of multiple sclerosis meeting McDonald criteria for MS at the screening visit and having either one of the following treatment status: * Naïve to disease modifying (DM) treatment or no DM treatment for more than 2 years * Or curre...
Teriflunomide HMR1726 is an investigational small molecule being developed by Sanofi for multiple sclerosis and renal impairment. It is currently in Phase 3 clinical development. The drug is being studied for its effects on immune cell subsets in multiple sclerosis patients and for pharmacokinetics in subjects with severe renal impairment.
Teriflunomide HMR1726 is developed by Sanofi, a company traded under the ticker SNY. Sanofi is conducting clinical trials to evaluate the drug's safety and efficacy in multiple sclerosis and renal impairment. The drug is currently in Phase 3 development.
Teriflunomide HMR1726 is in Phase 3 clinical development. It is an investigational drug, not yet approved by regulatory authorities. Sanofi has completed two clinical trials involving the drug, including a Phase 3 study in multiple sclerosis patients.
Teriflunomide HMR1726 has been studied in two completed trials. NCT01239459 evaluated a single 14 mg dose in subjects with severe renal impairment. NCT01863888 examined its effect on immune cell subsets in multiple sclerosis patients. Both trials are completed, with no active trials currently ongoing.
Teriflunomide HMR1726 is a specific investigational formulation of teriflunomide being developed by Sanofi. While teriflunomide is a known medication for multiple sclerosis, this particular drug candidate is still in clinical development and has not been approved. It is being studied for use in multiple sclerosis and renal impairment.